Embrella CE marks blood clot deflector
This article was originally published in Clinica
Embrella Cardiovascular has CE marked its Embrella Embolic Deflector for sale in Europe. The device acts as a protective shield, deflecting blood clots from arteries that lead to the head and stopping them from blocking blood vessels in the brain. This should decrease the incidence of ischaemic stroke during procedures such as transcatheter aortic valve implantation (TAVI), which can dislodge debris and calcific particles that are found in diseased arteries. TAVI is approved in Europe for patients with severe aortic stenosis, and Embrella (Wayne, Pennsylvania) expects the global market to grow from $200m in 2009 to over $1.7bn in 2015. The company hopes its device will become the standard of care in all TAVI procedures.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.